A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
Biogen Canada Inc. announced today that Health Canada has issued marketing authorization with conditions (Notice of Compliance ...
Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...
Pete Stavropoulos; Analyst; Cantor Fitzgerald & Co. Good afternoon and welcome to Voyager Therapeutics fourth-quarter and year-end 2024 financial results conference call. (Operator Instructions) ...
It was October 2024, and my husband Andrew had just been diagnosed with motor neurone disease (MND) aged 51 – which affects ...
March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
On Slide 4, you can see our pipeline. I won't go into a lot of detail here, other than to point out that our SOD1 silencing gene therapy program did move back into the research stage, as we ...
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback